logo

CRIS

Curis·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

CRIS fundamentals

Curis (CRIS) released its earnings on Nov 6, 2025: revenue was 3.18M (YoY +8.50%), beat estimates; EPS was -0.49 (YoY +71.18%), beat estimates.
Revenue / YoY
3.18M
+8.50%
EPS / YoY
-0.49
+71.18%
Report date
Nov 6, 2025
CRIS Earnings Call Summary for Q3,2025
  • CLL Trial Launch: Phase II study of emavusertib + BTKi in CLL patients with PR but no CR, targeting MRD negativity. Enrollment begins Q4 2025, data at ASH 2026.
  • AML MRD Success: 4/8 patients achieved undetectable MRD within 8 weeks in triplet study; no disease progression.
  • Financial Stability: $9.1M cash as of Q3; expects to fund operations into 2026.
  • FDA Alignment: CLL protocol submissions aligned with FDA; PCNSL study on track for accelerated submissions.
EPS
Revenue

Revenue & Expenses

CRIS has released its 2025 Q3 earnings report, with revenue of 3.18M, reflecting a YoY change of 8.36%, and net profit of -7.73M, showing a YoY change of 23.41%. The Sankey diagram below clearly presents CRIS's revenue sources and cost distribution.

Key Indicators

Curis (CRIS) key financial stats and ratios, covering profitability, financial health, and leverage.
Curis (CRIS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Curis (CRIS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Curis (CRIS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Curis (CRIS) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Curis (CRIS) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield